Psyence Biomedical Ltd’s Post

Thoughts on this? >> Scholar Rock aims to raise $275M; Vincerx to reshuffle pipeline focus >> Comment below! >>> lqventures.com #pharma #healthcare #biotech #pharmaceutical #productmarketing

Thoughts on this? >> Rapport, a clinical-stage neuroscience biotech, files for IPO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #healthcare #biotech

Three biotech updates you should know about: 1️⃣ 𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 Ascendis Pharma 𝗗𝗿𝘂𝗴 𝗳𝗼𝗿 𝗥𝗮𝗿𝗲 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻 🏥 After overcoming an earlier rejection, Yorvipath has now received FDA approval for treating hypoparathyroidism. This is a major achievement for Ascendis Pharma and a big step forward for patients with this rare endocrine condition. 2️⃣ Synchron 𝗕𝗿𝗮𝗶𝗻-𝗖𝗼𝗺𝗽𝘂𝘁𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝗳𝗮𝗰𝗲 (𝗕𝗖𝗜) 𝗖𝗹𝗲𝗮𝗿𝘀 𝗦𝗮𝗳𝗲𝘁𝘆 𝗦𝘁𝘂𝗱𝘆 🧠 Synchron’s brain-computer interface technology has successfully passed a year-long safety study, demonstrating its potential as a groundbreaking therapy for neurological conditions. 3️⃣ Frazier Life Sciences 𝗥𝗮𝗶𝘀𝗲𝘀 $𝟲𝟯𝟬𝗠 𝗳𝗼𝗿 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 💰 In a huge boost for the industry, Frazier Life Sciences has raised an impressive $630 million to support small and mid-cap biotech companies. This investment could be a game-changer for the development of new therapies. #BiotechNews #FDAApproval #BrainComputerInterface #LifeSciences

Thoughts on this? >> Rapport, a clinical-stage neuroscience biotech, files for IPO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing

Small molecules, due to their size and properties, have a greater chance of reaching their target within the brain. New research from CB Insights reinforces the brevity behind small-molecule therapies in a recent study highlighting that nearly two-thirds of FDA-approved drugs between 2013 and 2022 were small molecules ("2024 Tech Trends in Healthcare & Lifesciences"). How can small molecules revolutionize drug development? Stay tuned for more updates on how Curadev's unique pipeline is poised to transform the landscape of #ClinicalBiotech! Image provided by CB Insights #CuradevCares #SmallMolecules #LiverFibrosis #HealthcareInnovation #clinicalresearch

Roadshow: Arovella Therapeutics ASX: ALA Non-Deal Road Show 3-5 July 2024 Blue Ocean Equities will be hosting Arovella Therapeutics for a non-deal road show. Presenting will be CEO & Managing Director, Michael Baker 3 July - Sydney 4 July - Brisbane 5 July - Melboure Manufacturing and next steps for Arovella are to be discussed at the presentation. If you would like to catch up with Michael please contact me. Arovella has recently achieved a significant milestone by completing process development for its patent protected manufacturing process required for large-scale Good Manufacturing Practice (#GMP) manufacturing of its lead product, ALA-101. This achievement paves the way for Arovella to proceed with engineering and GMP batches to produce material for phase 1 clinical trials. This milestone facilitates Arovella’s pipeline expansion for its CAR-iNKT cell platform. The manufacturing process can be applied to all of Arovella’s future CAR-iNKT cell products, significantly reducing the time required to proceed from proof-of-concept data to clinical manufacture for programs with new CARs.

In Edison Group’s last BB Biotech (BION) review note, published in May 2024, they noted that the biotech sector was eagerly awaiting some key milestones, the most important being Alnylam Pharmaceuticals’ late-stage clinical trial of vutrisiran for patients with ATTR cardiomyopathy, a deadly heart disease. Alnylam, which comprised 4.3% of BION’s portfolio at end March 2024, released very positive, statistically significant, Phase III trial results this week. Assuming regulatory clearance, Alnylam expects that vutrisiran has the potential to become the new standard of care for the treatment of this disease, driving substantial future growth for the company. These results may have favourable implications for sentiment across the broader global biotech sector, and for Ionis Pharmaceuticals, BION’s largest portfolio position, which is also developing gene-silencing technology.   #biotech #Markets #Investment  https://lnkd.in/esKu7Evt  

📄 Analyst Report   Petra Capital Pty Ltd has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.   The author noted:   “FY24 saw OCC’s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28/sh TP offering >3x upside.”   Take a look 👉 https://lnkd.in/gw7A9DAe   $OCC #innovation #biotech #pharma #regenerativemedicine #healthcare #growth

Multidisciplinary drug discovery company Argent BioPharma Ltd (LSE:MXC, OTC:RGTLF, ASX:RGT) has struck up a strategic collaboration with SINTEF, one of Europe’s largest independent research organisations, to tackle the critical clinical challenge of chronic wound management with shares trading higher as a result. The collaboration will help the biotech expand into new therapeutic areas with a focus on nano-formulations. Chronic wounds pose a major public health issue, inflicting severe suffering on patients and affecting large numbers of people around the world. These wounds present complex challenges such as antibiotic-resistant infections, impenetrable biofilms and deteriorating local tissue health. More at #Proactive #ProactiveInvestors #ASX #RGT #Biotech #Medtech #Health #Therapeutics http://ow.ly/mVmo105GhEG

Thoughts on this? >> #AAIC24: Anavex’s new analysis of its Alzheimer’s pill shows mixed results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #healthcare #biotech